Compare ENLV & DH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENLV | DH |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 283.1M |
| IPO Year | 2014 | 2021 |
| Metric | ENLV | DH |
|---|---|---|
| Price | $1.03 | $1.11 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $13.00 | $3.43 |
| AVG Volume (30 Days) | 199.5K | ★ 360.9K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,521,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $0.97 |
| 52 Week High | $2.10 | $4.70 |
| Indicator | ENLV | DH |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 29.40 |
| Support Level | $1.00 | $1.07 |
| Resistance Level | $1.23 | $1.29 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 2.78 | 34.02 |
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.